Saturday 17 October 2026
Export IRLA’s income statement to Excel — free account
Quince Therapeutics, Inc.
IRLA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.9%, free cash flow fell 63.7% and total debt rose 28.2%, each against the same quarter a year earlier.
32.17
1.06
−3.19%
Follow IRLA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 784.09% | (192.90%) | 3,016.49% | (247.78%) |
+8 more TTM periods Free account |
|
| (76.68%) | (49.42%) | (80.75%) | (48.20%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(80.12%) | (190.28%) | 425.53% | (1,509.78%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(7.65) | (86.52) | (166.77) | (144.47) | |
Free Cash Flow |
(46.92) | (39.45) | (41.78) | (38.98) | |
Capital Expenditures |
— | — | (0.35) | (0.48) | |
| Other line items | |||||
Cash ROIC |
(58.18%) | (116.60%) | (10,603.30%) | (86.87%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.02) | (0.06) | 0.04 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.51 | 1.19 | 0.49 | 0.68 | |
Depreciation/Fixed assets |
(0.66) | (1.05) | (1.47) | (1.94) | |
Capex/Depreciation |
0.00 | 0.00 | 0.40 | 0.40 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.65) | (86.52) | (165.37) | (142.68) | |
Capex per Share |
0.00 | 0.00 | (1.41) | (1.78) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates